Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

599
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
599
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

398
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
398
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

257
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
257
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

265
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
265
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

1.8K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Dystonia caused by a mutation in the KMT2B gene].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same author

[Parkinson's Disease and Pregnancy. Resolution of The National Society for the Study of Parkinson's Disease and Movement Disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Familial hemifacial spasm].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Art and creativity in Parkinson's disease: the mysterious effects of dopamine].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2025
Same author

[Tremor-dominant form of Parkinson's disease].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2024
Same author

[Dolichoectasia of the basilar artery caused by cystic medial degeneration, as a cause of neurovascular conflict with damage to the trigeminal, facial and vestibulocochlear nerves].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2023
Same journal

[The role of the cerebellum in the coordination of brain activity and the development of autism spectrum disorders].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[A clinical case of anxiety-hypochondriacal depression with extensive somatized symptoms in the elderly].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[De novo variant in the ATP2B2 gene as a cause of neuropsychiatric developmental disorder].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Electroencephalographic predictors of olfactory stimulus discrimination in COVID-19 survivors].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Effect of long-term carbamazepine therapy on bone metabolism in women with epilepsy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
Same journal

[Glial-derived neurotrophic factor and neuropsychological status in COVID-19 survivors].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·2026
See all related articles

Related Experiment Video

Updated: Jul 21, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K

[Tardive dyskinesia].

Z A Zalyalova1,2,3

  • 1Kazan State Medical University, Kazan, Russia.

Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|July 25, 2023
PubMed
Summary
This summary is machine-generated.

Tardive dyskinesia (TD) is a movement disorder from dopamine receptor blockers. Prevention and careful prescribing are key, with options like VMAT2 inhibitors or neuromodulation for severe cases.

Keywords:
antipsychoticsbotulinum toxindopamine receptor blockersmonoamine reuptake inhibitorneuromodulationoro-bucco-lingual dyskinesiastardive dyskinesiatetrabenazine

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K

Related Experiment Videos

Last Updated: Jul 21, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
05:52

Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis

Published on: November 21, 2013

15.0K

Area of Science:

  • Neurology
  • Pharmacology

Context:

  • Tardive dyskinesia (TD) is a serious side effect of long-term dopamine receptor-blocking drug use.
  • Prevention is crucial due to the often irreversible nature of TD.

Purpose:

  • To review current understanding and management strategies for tardive dyskinesia.
  • To highlight the need for improved diagnostic methods and clinical trials.

Summary:

  • Best practices include judicious antipsychotic prescribing and reducing dopamine receptor blocker use in non-psychiatric settings.
  • Treatment options include switching to lower D2 affinity antipsychotics, VMAT2 inhibitors (tetrabenazine), botulinum therapy, or amantadine.
  • Neuromodulation is a consideration for refractory cases, though evidence for most TD testing methods is limited.

Impact:

  • Emphasizes the importance of evidence-based prescribing to minimize TD incidence.
  • Identifies potential therapeutic avenues and underscores the urgent need for further research and clinical trials in TD management.